Therefore, compared to the other three groups, every protein level and mRNA level, the targets of IRF1 and IRF9 expression levels in the IFNγ and STAT3 inhibitor combination group were the highest and the SOCS1 lowest in NSCLC cells (H1299, H1975, PC9, and H3255) (Figures 5(e)–5(h)), suggesting the inhibition of STAT3 phosphorylation could further activates the IFNγ/JAK/STAT1 signalling pathway. The gene discussed is IRF1; the disease is non-small cell lung carcinoma.